Digestive Health

Social media platforms provide an opportunity for pharmacists to create accurate content on inflammatory bowel disease for younger patients.

Adalimumab-aaty (Yuflyma) prefilled syringes and autoinjectors are now fully interchangeable with the reference product adalimumab (Humira) across marketed dosage forms and strengths.

Pharmacists can substitute ustekinumab with the biosimilar at the pharmacy level, depending on their state laws.

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.

Selarsdi is interchangeable for all indications of ustekinumab, including treatment of psoriatic arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis.

Researchers investigated the health benefits, utilization, harms, and costs associated with the use of alternative methods for colorectal cancer screening in Australia.

Exploring data from the past 20 years, researchers investigated the end-organ complications from alcohol in adolescents and young adults.

Investigators note there were no safety signals related to the vaccine candidate, and participants who developed E. coli disease received treatment and care.

Help your patients overcome tummy troubles with trusted OTC products that relieve bloating, heartburn, and more, promoting smooth and happy digestion.

Patients who achieved clinical remission at 1 year in VIVID-1 maintain clinical remission at 92.9% at 2 years with the Crohn Disease Activity Index.

Sarah Gray, PharmD, GAICD, discussed her experience as a pharmacist who added nutrition counseling to her clinical expertise.

Sarah Gray, PharmD, GAICD, known as the Nutrition Pharmacist, joined Drug Topics to discuss her experience with patients looking to begin healthier lifestyles at the start of a new year.

Researchers performed a systematic literature review of the efficacy of amitriptyline for treating patients with irritable bowel syndrome.

Researchers conducted a literature research review to further understand the current evidence regarding diagnosis and treatment for peptic ulcer disease.

US News & World Report nutrition experts detailed the best types of diets for maintaining patient health in 2025.

Check out this list of our top 5 most read digestive health stories from the year 2024.

Researchers explored the impacts of natural bioactive compounds for the treatment of acute pancreatitis.

Kathryn Litten, PharmD, discussed the pharmacist’s role in helping patients manage metabolic dysfunction-associated steatotic liver disease.

Researchers observed the use of a discrete event simulation using non-invasive tests for patients with nonalcoholic steatohepatitis.

Researchers assessed the importance of a nutritious diet and the role pharmacists play in providing dietary management services.

Researchers explored literature on the health benefits of the 4 main functional dietary components—prebiotics, probiotics, synbiotics, and postbiotics.

Researchers explored the disease activity of patients with axial spondylarthritis after various modifications to their diets.

Researchers aimed to address the associations between gout and ischemic events, specifically ischemic colitis.

Researchers explored the benefits of tai chi and prevalence of liver disease in patients with osteoarthritis.

Researchers analyzed the impact of the COVID-19 pandemic on outcomes for patients with pancreatic cancer living in England.

Researchers compared the racial and ethnic representation of participants in food allergen trials with patients who experience food allergies.

Researchers attempted to understand the evolving epidemiology of gastrointestinal stromal tumors in major organ sites.

Researchers from Celltrion USA presented their post hoc analysis from the LIBERTY studies at the American College of Gastroenterology 2024 Annual Scientific Meeting.

Researchers addressed the gut-first hypothesis of Parkinson disease by identifying how mucosal damage impacts risk of development.

Johnson & Johnson announced results from its phase 3 GRAVITI trial exploring guselkumab’s results in subcutaneous (SC) induction and maintenance therapy for treating Crohn’s disease.